Syros Pharmaceuticals, Inc. Executive Compensation (FY23)
SYRS · Executive and director compensation, fiscal 2022 to 2023
Chief executive, fiscal 2023 ◇ Conley Chee |
Velarion Member: every covered company in one industry, with dashboards, peer screens and board-ready briefs. Three seats, one year.
The paid brief on Syros Pharmaceuticals, Inc.
Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
From $499 for the board report; $2,400 for both.
Data as of October 22, 2026Latest filing (10-K): April 23, 2024
1 filing cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Velarion Intel, one year, every company
177 figures on this page, cited to the filing that reported them. See the citations
Syros Pharmaceuticals, Inc. does not file an annual proxy statement (DEF 14A). Its executive compensation is disclosed directly in its Form 10-K (Part III), which is the filing cited throughout this document. A Form 10-K does not carry a disclosed compensation peer group or a say-on-pay vote; those sections are absent from this document for that reason, not from a data gap.
More on Syros Pharmaceuticals, Inc.
Five data products on this company. Each one is requested through the developer setup page.
- Peer Disclosure Audit$5The comparison companies this board named, each one tied to the filing that lists it.How to get Peer Disclosure Audit
- Governance Provisions PullfreeThe governance provisions as the proxy states them: board leadership, committee membership, and shareholder rights.How to get Governance Provisions Pull
- Say-on-Pay Risk Signal$9A risk band for the next say-on-pay vote, with the support history and the peer comparison behind it.How to get Say-on-Pay Risk Signal
- NEO Comp Report$24Every named executive officer’s pay by element and year, with the citation behind each figure.How to get NEO Comp Report
- Board Comp Report$24What each non-employee director was paid, the standing fee schedule, and the equity each one holds at year end.How to get Board Comp Report
What changed from fiscal 2022 to fiscal 2023
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
Chief executive of record: Nancy Simonian → Conley Chee
Frequently asked questions
Answers drawn from the data on this page.
Who is Syros Pharmaceuticals, Inc.'s chief executive and what were they paid?
Conley Chee was paid $1,041,697 in total compensation as President & Chief Executive Officer for fiscal 2023.
Executive compensation
Every element reported for each named executive officer, by fiscal year.
Fiscal 2022
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Nancy Simonian Former President & Chief Executive Officer | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
David Roth Chief Medical Officer | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Eric Olson Former Chief Scientific Officer | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Jason Haas Chief Financial Officer | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Fiscal 2023
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Nancy Simonian Former President & Chief Executive Officer Departed during or after this year | ◇ | — | ◇ | — | ◇ | — | ◇ | ◇ |
Conley Chee President & Chief Executive Officer | ◇ | — | ◇ | — | ◇ | — | ◇ | ◇ |
Eric Olson Former Chief Scientific Officer Departed during or after this year | ◇ | — | ◇ | — | — | — | ◇ | ◇ |
David Roth Chief Medical Officer | ◇ | — | ◇ | — | ◇ | — | ◇ | ◇ |
Jason Haas Chief Financial Officer | ◇ | — | ◇ | — | ◇ | — | ◇ | ◇ |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.
Equity awards granted
Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2023
| Officer | Award | Grant date | Threshold units | Target units | Units granted | Maximum units | Exercise price | Grant date fair value |
|---|---|---|---|---|---|---|---|---|
| Conley Chee | PSU | ◇ | — | ◇ | — | — | — | ◇ |
| Conley Chee | RSU | ◇ | — | — | ◇ | — | — | — |
| Conley Chee | RSU | ◇ | — | — | ◇ | — | — | — |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.
Outstanding awards
Awards still held at fiscal year end.
As disclosed at fiscal 2023 year end
| Officer | Award | Unvested units | Market value of unvested units | Exercise price | Expires |
|---|---|---|---|---|---|
| Nancy Simonian | PSU | ◇ | ◇ | — | — |
| RSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | 10/5/2032 | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | 2/16/2031 | |
| RSU | ◇ | ◇ | — | — | |
| Conley Chee | PSU | ◇ | ◇ | — | — |
| RSU | ◇ | ◇ | — | — | |
| PSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | 10/5/2032 | |
| RSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | 9/26/2031 | |
| RSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | 2/14/2032 | |
| Jason Haas | PSU | ◇ | ◇ | — | — |
| RSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | 10/11/2031 | |
| Option | ◇ | — | ◇ | 10/5/2032 | |
| RSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | 2/14/2032 | |
| RSU | ◇ | ◇ | — | — | |
| David Roth | PSU | ◇ | ◇ | — | — |
| RSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | 10/5/2032 | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | 2/14/2032 | |
| RSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | 2/16/2031 | |
| Option | ◇ | — | ◇ | 2/12/3030 | |
| Eric Olson | Option | ◇ | — | ◇ | 1/16/2024 |
| Option | ◇ | — | ◇ | 1/16/2024 | |
| Option | ◇ | — | ◇ | 1/16/2024 | |
| Option | ◇ | — | ◇ | 1/16/2024 | |
| Option | ◇ | — | ◇ | 1/16/2024 | |
| Option | ◇ | — | ◇ | 1/16/2024 | |
| Option | ◇ | — | ◇ | 1/16/2024 | |
| Option | ◇ | — | ◇ | 1/16/2024 | |
| Option | ◇ | — | ◇ | 1/16/2024 |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.
Director compensation
What each non-employee director was paid.
Fiscal 2023
| Director | Fees earned in cash | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|
Peter Wirth | ◇ | ◇ | ◇ | — | — | — | ◇ |
Marsha H. Fanucci | ◇ | ◇ | ◇ | — | — | — | ◇ |
S. Gail Eckhardt | ◇ | ◇ | ◇ | — | — | — | ◇ |
Richard A. Young | ◇ | ◇ | ◇ | — | — | — | ◇ |
Deborah Dunsire | ◇ | ◇ | ◇ | — | — | — | ◇ |
Andrew M. Oh | ◇ | ◇ | ◇ | — | — | — | ◇ |
Timothy C. Tyson | ◇ | ◇ | ◇ | — | — | — | ◇ |
Mark J. Alles | ◇ | ◇ | ◇ | — | — | — | ◇ |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.
Director fee schedule
The standing retainers and premiums the board pays, as published.
| Board cash retainer | ◇ |
| Board chair premium | ◇ |
| Audit committee chair | ◇ |
| Audit committee member | ◇ |
| Compensation committee chair | ◇ |
| Compensation committee member | ◇ |
| Nominating and governance chair | ◇ |
| Nominating and governance member | ◇ |
Disclosed peer group
The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Ask our research desk — $99, 24h, every figure cited to its filing.
Sample answer — “What is the CEO’s total compensation?”
- Conley Chee (President & Chief Executive Officer), FY2023 total compensation $1,041,697 (base salary $479,092) [exec_comp, SEC accession 0001193125-24-105876, filed 2024-04-23]What this page does not include
Everything above is a fact Syros Pharmaceuticals, Inc. disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $1,500Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $499Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion IntelligenceAdviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Inquire about accessMultiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion IntelligenceCitations
Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
177 figures on this page, cited to the filing that reported them.
177 cited to the filing
Documents cited
- 0001193125-24-105876Director Compensation · Outstanding Equity Awards at Fiscal Year End 2023
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “Syros Pharmaceuticals, Inc. executive compensation, FY2022–FY2023.” https://intel.velarion.ai/comp/SYRS (accessed 2026).
Short form: data: Velarion
The paid brief for Syros Pharmaceuticals, Inc.
Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
From $499 for the board report; $2,400 for both.
1 filing cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about Syros Pharmaceuticals, Inc. and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Free to read and cite. Redistribution or bulk use of the dataset requires a data license. Talk to us about the data license.
Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
author = {{Velarion Company Intelligence}},
title = {Velarion database: executive and board compensation data},
year = {2026},
version = {2026Q3},
doi = {10.5281/zenodo.22283854},
publisher = {Zenodo},
url = {https://doi.org/10.5281/zenodo.22283854}
}